Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Change in Receivables (2016 - 2025)

Tandem Diabetes Care's Change in Receivables history spans 13 years, with the latest figure at $42.0 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 247.71% year-over-year to $42.0 million; the TTM value through Dec 2025 reached $56.8 million, up 173.2%, while the annual FY2025 figure was $56.8 million, 173.2% up from the prior year.
  • Change in Receivables reached $42.0 million in Q4 2025 per TNDM's latest filing, up from $1.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $42.0 million in Q4 2025 to a low of -$22.8 million in Q1 2023.
  • Average Change in Receivables over 5 years is $5.6 million, with a median of $7.1 million recorded in 2021.
  • Peak YoY movement for Change in Receivables: plummeted 201.17% in 2021, then skyrocketed 247.71% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $24.2 million in 2021, then crashed by 87.47% to $3.0 million in 2022, then skyrocketed by 84.41% to $5.6 million in 2023, then surged by 115.96% to $12.1 million in 2024, then surged by 247.71% to $42.0 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Change in Receivables are $42.0 million (Q4 2025), $1.3 million (Q3 2025), and $2.7 million (Q2 2025).